Annotation Detail

Information
Associated Genes
SGK1
Associated Variants
SGK1 OVEREXPRESSION ( ENST00000367858.10 )
SGK1 OVEREXPRESSION ( ENST00000367858.10 )
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment. HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1731
Gene URL
https://civic.genome.wustl.edu/links/genes/5225
Variant URL
https://civic.genome.wustl.edu/links/variants/693
Rating
4
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Alpelisib,SGK1-Inh
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
27451907
Drugs
Drug NameSensitivitySupported
AlpelisibSensitivitytrue
SGK1-InhSensitivitytrue